KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,037,460 | -21.6% | 32,543 | -1.2% | 0.00% | 0.0% |
| Q2 2023 | $1,324,051 | +110329.6% | 32,953 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $1,199 | -5.4% | 28,091 | +6.5% | 0.00% | -50.0% |
| Q4 2022 | $1,267 | -99.9% | 26,384 | +13.0% | 0.00% | +100.0% |
| Q3 2022 | $879,000 | +57.0% | 23,357 | +15.3% | 0.00% | 0.0% |
| Q2 2022 | $560,000 | -35.2% | 20,251 | +27.5% | 0.00% | 0.0% |
| Q1 2022 | $864,000 | +6.3% | 15,886 | +14.3% | 0.00% | 0.0% |
| Q4 2021 | $813,000 | +44.9% | 13,902 | -2.0% | 0.00% | 0.0% |
| Q3 2021 | $561,000 | -2.3% | 14,185 | +5.0% | 0.00% | 0.0% |
| Q2 2021 | $574,000 | -31.8% | 13,505 | -1.2% | 0.00% | 0.0% |
| Q1 2021 | $842,000 | -12.3% | 13,675 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $960,000 | +254.2% | 13,611 | +93.8% | 0.00% | – |
| Q3 2020 | $271,000 | -7.8% | 7,023 | -10.4% | 0.00% | – |
| Q2 2020 | $294,000 | – | 7,834 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |